Extended skin allo- and xenograft survival in mice treated with rapamycin, antilymphocyte serum, and donor-specific bone marrow transfusion.
Hale
D A
DA
Department of Surgery, Deaconess Hospital, Boston, Massachusetts 02215, USA.
Gottschalk
R
R
Fukuzaki
T
T
Wood
M L
ML
Maki
T
T
Monaco
A P
AP
D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003131:Combined Modality Therapy; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D051379:Mice; D008806:Mice, Inbred AKR; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008815:Mice, Inbred Strains; D011090:Polyenes / Q000627:therapeutic use; D051381:Rats; D011912:Rats, Inbred ACI; D020123:Sirolimus; D016038:Skin Transplantation / Q000276:immunology*; D014183:Transplantation, Heterologous / Q000276:immunology*; D014184:Transplantation, Homologous / Q000276:immunology*
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011090:Polyenes; D020123:Sirolimus